Return to Clinical Trials Search Results
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Primary;
To evaluate the effect of baricitinib 4-mg once daily (QD) compared to placebo on disease progression in patients with COVID-19 infection.
Key Secondary: To evaluate the effect of baricitinib 4-mg QD compared to placebo on clinical outcomes in patients with COVID-19 infection
Primary;
To evaluate the effect of baricitinib 4-mg once daily (QD) compared to placebo on disease progression in patients with COVID-19 infection.
Key Secondary: To evaluate the effect of baricitinib 4-mg QD compared to placebo on clinical outcomes in patients with COVID-19 infection
Recruitment Status
Past Studies